Jupiter Neurosciences, Inc. (JUNS) Future Price to Earnings
Jupiter Neurosciences Inc (JUNS) strong scientific foundation in brain molecule delivery drives the dynamics of the company's expected P/E ratio, which currently stands at 0.00. Business development relies on a trial schedule that remains independent of GDP. The proprietary oral administration system protects yields from dumping, as clearly illustrated by this multiplier chart.
Summary analytical data breakdowns for jupiterneurosciences.com (JUNS)
- current price and projected stock value:
- market capitalization details:
- balance sheet equity data:
- company total debt and liquidity indicators:
Total Debt to Capital Jupiter Neurosciences Inc|JUNS - Long-Term Liabilities to Capital|Short-Term Debt to Equity Jupiter Neurosciences|JUNS - Aggregate Debt Obligations|Debt to Book Value Jupiter Neurosciences, Inc.|JUNS - Company Long-Term Loans and Borrowings|Company Short-Term Debt Jupiter Neurosciences|Quick Ratio jupiterneurosciences.com
- earnings and market ratios statistics:
JUNS - Company Net Income|Future Profit Jupiter Neurosciences Inc|JUNS - P/E Multiple|Future Price to Earnings Jupiter Neurosciences Inc|JUNS - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jupiter Neurosciences, Inc.|JUNS - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Jupiter Neurosciences|JUNS - Net earnings per share for the last four quarters|Quarterly EPS earnings growth jupiterneurosciences.com|JUNS - Net earnings per share growth this year|Earnings growth forecast for next year Jupiter Neurosciences Inc
- revenue and sales proceeds data:
Fundamental valuation:Jupiter Neurosciences Inc JUNS
To protect capital during periods of turbulence, it is crucial for investors to monitor the ratio of the current market value of Jupiter Neurosciences Inc (JUNS) to its expected annual earnings, as reflected in the fluctuations of the company's forward P/E. This indicator captures the dynamics of future income revaluation, confirming the business's status as a defensive asset due to stable demand for biotechnology that remains independent of global macroeconomic cycles.
Direct competitors
Projected Price to Earnings BIIB (Biogen)|Forward P/E Multiple Neurocrine (NBIX)|Future Price to Earnings Regencell RGC|AXSM (Axsome Corp) - Price to Expected Earnings Ratio|ACADIA Pharmaceuticals - Forward P/E Multiple|Market Cap to Projected Earnings xenon-pharma.com XENE|VKTX (Viking Therapeutics, Inc.) - Projected Price to Earnings|SUPN: Market Cap to Future Earnings Ratio|CPRX (Catalyst Pharmaceuticals Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Denali Corp DNLI|Future Price to Earnings Harmony Biosciences (HRMY)|BHVN (biohavenpharma.com) - Future Price to Earnings Multiple|Amylyx Pharmaceuticals, Inc. - Projected Price to Earnings|Future Price to Earnings Multiple TRVI|PRAX - Future Price to Earnings|AVXL (Anavex Life Sciences Corp) - Price to Future Earnings Ratio|CBLL: Forward P/E Multiple|Projected Price to Earnings Ratio Prothena (PRTA)|Projected Price to Earnings ALEC|Forward P/E Multiple Annexon Biosciences|Future Price to Earnings Omeros Corporation (OMER)|NGNE (Neurogene Therapeutics) - Future Price to Earnings Multiple|Future Price to Earnings AC Immune ACIU|voyagertherapeutics.com (VYGR) - Projected Price to Earnings Ratio|NMRA - Future Price to Earnings|Market Cap to Projected Earnings Scilex Holding SCLX|TVGN: Forward P/E Multiple|Projected Price to Earnings Alpha Cognition Inc.|CGTX (Cognition Therapeutics) - Forward P/E Multiple|inhibikase.com (IKT) - Market Cap to Projected Earnings|Forward P/E Multiple SAVA|ASRT - Projected Price to Earnings Ratio|Future Price to Earnings Coya Therapeutics COYA|VTGN: Price to Future Earnings Ratio|Ovid Rx - Forward P/E Multiple|acumenpharm.com (ABOS) - Projected Price to Earnings|CRVO: Forward P/E Multiple|Projected Price to Earnings Ratio Alterity Therapeutics Limited (ATHE)|Future Price to Earnings Clene Inc|PepGen Corp (PEPG) - Market Cap to Projected Earnings|Projected Price to Earnings RLMD (Relmada Therapeutics)|ANVS (annovisbio.com) - Future Price to Earnings Multiple|Forward P/E Multiple GRCE (Grace Therapeutics)|Market Cap to Projected Earnings Firefly Neuroscience, Inc. (AIFF)|KLTO - Future Price to Earnings|NRSN (NeuroSense Therapeutics) - Price to Future Earnings Ratio|RVPH: Forward P/E Multiple|Projected Price to Earnings MetaVia|Future Price to Earnings NeurAxis|HSDT (Helius Medical Technologies Inc.) - Market Cap to Future Earnings Ratio|Projected Price to Earnings PASG (Passage Bio, Inc.)|Forward P/E Multiple bionomics.com.au (NEUP)|Future Price to Earnings Minerva Neurosciences NERV|ATHA: Price to Future Earnings Ratio|ADXN - Future Price to Earnings|Market Cap to Projected Earnings Alzamend Neuro, Inc. ALZN|cyclerion.com (CYCN) - Future Price to Earnings|Price to Future Earnings Ratio PTIX|KTTA (Pasithea Therapeutics Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio Cortigent Medical CRGT|Projected Price to Earnings ATXI (Avenue Therapeutics, Inc.)|Forward P/E Multiple Brainstorm Cell Therapeutics Inc. (BCLI)|Future Price to Earnings Cara Therapeutics, Inc CARA|Future Price to Earnings Multiple CHRO|ELYM - Future Price to Earnings|Projected Price to Earnings Ratio Intra-Cellular Therapies|Longboard Pharmaceuticals, Inc. (LBPH) - Future Price to Earnings|MRNS: Market Cap to Future Earnings Ratio|Projected Price to Earnings NKGN|Forward P/E Multiple NeuroBo Pharma|Future Price to Earnings Sage Therapeutics, Inc. (SAGE)|SNPX: Price to Expected Earnings Ratio|Forward P/E Multiple TRVN (Trevena)|Market Cap to Projected Earnings Vigil Neuroscience Inc. (VIGL)|WENA: Projected Price to Earnings|Cerevel Corp - Market Cap to Future Earnings Ratio
